Cyteir Therapeutics, Inc. (CYT)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Cyteir Therapeutics, Inc. (CYT) with AI Score 47/100 (Weak). Cyteir Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing and commercializing next-generation precision oncology medicines. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 17, 2026Cyteir Therapeutics, Inc. (CYT) Healthcare & Pipeline Overview
Cyteir Therapeutics, Inc. is a clinical-stage biotechnology firm specializing in precision oncology, with its lead drug candidate, CYT-0851, targeting solid tumors and hematologic malignancies. Currently in Phase I/II trials, Cyteir aims to address unmet needs in cancer treatment through innovative, small molecule therapeutics, distinguishing itself in a competitive biotech landscape.
Investment Thesis
Cyteir Therapeutics presents a high-risk, high-reward investment opportunity within the biotechnology sector. The company's valuation is largely tied to the clinical success of CYT-0851, currently in Phase I/II trials. Positive data from these trials could serve as a major catalyst, driving significant stock appreciation. However, the company faces substantial risks, including clinical trial failures, regulatory hurdles, and the need for additional capital. With a market cap of $0.11 billion and a negative P/E ratio of -2.42, Cyteir's financial performance is closely linked to its research and development progress. Investors should closely monitor clinical trial updates and regulatory milestones to assess the potential for long-term value creation.
Based on FMP financials and quantitative analysis
Key Highlights
- CYT-0851 is in Phase I/II clinical trials, targeting solid tumors and hematologic malignancies.
- CYT-1853 is in preclinical development, expanding Cyteir's pipeline.
- Cyteir Therapeutics is a clinical-stage biotechnology company focused on precision oncology.
- The company is based in Lexington, Massachusetts, with 46 employees.
- Cyteir has a market capitalization of $0.11 billion.
Competitors & Peers
Strengths
- Novel drug candidates targeting DNA damage response.
- Clinical-stage development with CYT-0851 in Phase I/II trials.
- Experienced management team.
- Focus on precision oncology.
Weaknesses
- Limited financial resources.
- Reliance on clinical trial success.
- Small company size.
- Single lead product candidate.
Catalysts
- Upcoming: Data readout from Phase I/II clinical trials of CYT-0851 in solid tumors (Q4 2026).
- Upcoming: Initiation of Phase I clinical trials for CYT-1853 (H2 2027).
- Ongoing: Enrollment and progress in ongoing CYT-0851 clinical trials.
- Ongoing: Potential for strategic partnerships or collaborations.
Risks
- Potential: Clinical trial failures or delays.
- Potential: Regulatory setbacks or non-approval of drug candidates.
- Potential: Competition from other oncology therapies.
- Ongoing: Need for additional capital to fund research and development.
- Ongoing: Dependence on key personnel and scientific expertise.
Growth Opportunities
- Expansion of CYT-0851 into Combination Therapies: CYT-0851 is currently being evaluated as both a monotherapy and in combination with other cancer treatments. Exploring and validating its efficacy in combination therapies could significantly broaden its application and market potential. The combination therapy market in oncology is projected to reach $80 billion by 2028, offering a substantial growth opportunity for Cyteir.
- Advancement of CYT-1853 into Clinical Trials: CYT-1853, currently in preclinical development, represents a future growth driver for Cyteir. Successful completion of preclinical studies and initiation of Phase I clinical trials would validate the company's research and development capabilities and expand its pipeline. The timeline for IND submission is projected within the next 18-24 months, contingent on preclinical data.
- Strategic Partnerships and Collaborations: Cyteir can leverage strategic partnerships with larger pharmaceutical companies or research institutions to accelerate the development and commercialization of its drug candidates. Collaborations can provide access to additional funding, expertise, and market reach. The pharmaceutical industry is increasingly reliant on partnerships to drive innovation, making this a viable growth strategy.
- Geographic Expansion into International Markets: While currently focused on the US market, Cyteir could explore opportunities to expand its clinical trials and commercial operations into international markets, particularly Europe and Asia. These regions represent significant growth potential for oncology therapies, driven by increasing healthcare spending and aging populations. Market entry strategies would need to consider regulatory requirements and competitive landscapes.
- Targeting Additional Cancer Types: Cyteir's current clinical trials for CYT-0851 focus on specific solid tumors and hematologic malignancies. Expanding the drug's application to additional cancer types, based on its mechanism of action and preclinical data, could significantly increase its market potential. This would require further clinical trials and regulatory approvals, but could unlock substantial value for the company.
Opportunities
- Positive clinical trial results for CYT-0851.
- Expansion into new cancer types.
- Strategic partnerships with larger pharmaceutical companies.
- Advancement of CYT-1853 into clinical trials.
Threats
- Clinical trial failures.
- Regulatory hurdles.
- Competition from larger pharmaceutical companies.
- Need for additional capital.
Competitive Advantages
- Proprietary drug candidates (CYT-0851 and CYT-1853).
- Intellectual property protection (patents).
- Clinical trial data demonstrating efficacy and safety.
- Expertise in DNA damage response pathways in cancer.
About CYT
Cyteir Therapeutics, Inc., founded in 2012 and based in Lexington, Massachusetts, is a clinical-stage biotechnology company dedicated to developing and commercializing innovative precision oncology medicines. The company's primary focus is on addressing unmet medical needs in cancer treatment through targeted therapies. Their lead product candidate, CYT-0851, is a novel, oral, once-daily, small molecule drug currently undergoing Phase I/II clinical trials. These trials are evaluating CYT-0851 as a monotherapy and in combination therapy for patients with solid tumors and hematologic malignancies. CYT-0851 is designed to modulate the DNA damage response, a critical pathway in cancer cell survival. In addition to CYT-0851, Cyteir is also advancing CYT-1853, a preclinical asset targeting solid tumors and hematologic malignancies. Cyteir's strategy involves leveraging its scientific expertise to create differentiated therapies that improve patient outcomes in oncology. The company operates primarily in the United States, focusing on research, development, and clinical trials to bring its innovative therapies to market.
What They Do
- Develop precision oncology medicines.
- Conduct Phase I/II clinical trials for CYT-0851.
- Develop CYT-0851 as a monotherapy for solid tumors and hematologic malignancies.
- Develop CYT-0851 for combination therapy in solid tumors and hematologic malignancies.
- Conduct preclinical trials for CYT-1853.
- Research and develop targeted cancer therapies.
Business Model
- Develop and patent novel oncology drugs.
- Conduct clinical trials to demonstrate safety and efficacy.
- Seek regulatory approval from the FDA and other agencies.
- Commercialize approved drugs through sales and marketing efforts, or through partnerships.
Industry Context
Cyteir Therapeutics operates within the highly competitive biotechnology industry, which is characterized by rapid innovation and significant regulatory oversight. The oncology market, in particular, is experiencing substantial growth, driven by an aging population and advancements in personalized medicine. Cyteir's focus on precision oncology positions it within a high-growth segment of the market. However, the company faces competition from larger pharmaceutical companies and other biotechnology firms developing novel cancer therapies. Success in this industry requires strong scientific expertise, efficient clinical trial execution, and effective commercialization strategies.
Key Customers
- Patients with solid tumors.
- Patients with hematologic malignancies.
- Oncologists and hematologists.
- Hospitals and cancer centers.
Financials
Chart & Info
Cyteir Therapeutics, Inc. (CYT) stock price: Price data unavailable
Latest News
-
Stocks That Hit 52-Week Lows On Thursday
benzinga · Apr 28, 2022
-
Stocks That Hit 52-Week Lows On Tuesday
benzinga · Apr 26, 2022
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for CYT.
Price Targets
Wall Street price target analysis for CYT.
MoonshotScore
What does this score mean?
The MoonshotScore rates CYT's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Competitors & Peers
Leadership: Markus F. Renschler
CEO
Markus F. Renschler serves as the CEO of Cyteir Therapeutics, bringing extensive experience in the biotechnology and pharmaceutical industries. Prior to joining Cyteir, he held leadership positions at several companies, including Agios Pharmaceuticals and Novartis. His background includes expertise in drug development, commercialization, and strategic planning. Renschler holds an MD from Ludwig Maximilian University of Munich and an MBA from INSEAD.
Track Record: Since becoming CEO, Markus F. Renschler has focused on advancing Cyteir's clinical programs, particularly the Phase I/II trials for CYT-0851. He has also overseen the preclinical development of CYT-1853 and has been instrumental in securing funding for the company's research and development efforts. His leadership is focused on driving innovation and achieving key milestones in the development of novel cancer therapies.
Common Questions About CYT
What does Cyteir Therapeutics, Inc. do?
Cyteir Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing and commercializing next-generation precision oncology medicines. Their lead product candidate, CYT-0851, is a novel, oral, once-daily, small molecule drug currently in Phase I/II clinical trials for both monotherapy and combination therapy in patients with solid tumors and hematologic malignancies. Cyteir aims to improve patient outcomes by targeting the DNA damage response pathway in cancer cells, offering a potentially more effective and targeted approach to cancer treatment.
What do analysts say about CYT stock?
Analyst coverage of Cyteir Therapeutics is currently limited, reflecting its status as a clinical-stage biotechnology company. Key valuation metrics are primarily driven by the potential success of CYT-0851 in clinical trials. Investors should monitor analyst reports for updates on clinical trial data, regulatory milestones, and financial projections. Given the inherent risks associated with biotechnology investments, analyst opinions may vary widely based on their assessment of the company's pipeline and market potential. The company's negative P/E ratio reflects its current lack of profitability.
What are the main risks for CYT?
Cyteir Therapeutics faces several key risks inherent to the biotechnology industry. The primary risk is the potential failure or delay of clinical trials for CYT-0851 and CYT-1853. Positive clinical data is crucial for regulatory approval and commercial success. The company also faces regulatory risks, including the possibility of non-approval or delays in the approval process. Furthermore, Cyteir requires significant capital to fund its research and development activities, and may need to raise additional funds through equity or debt financing, which could dilute existing shareholders. Competition from larger pharmaceutical companies with greater resources also poses a significant threat.
What are the key factors to evaluate for CYT?
Cyteir Therapeutics, Inc. (CYT) currently holds an AI score of 47/100, indicating low score. Key strength: Novel drug candidates targeting DNA damage response.. Primary risk to monitor: Potential: Clinical trial failures or delays.. This is not financial advice.
How frequently does CYT data refresh on this page?
CYT prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven CYT's recent stock price performance?
Recent price movement in Cyteir Therapeutics, Inc. (CYT) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Novel drug candidates targeting DNA damage response.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider CYT overvalued or undervalued right now?
Determining whether Cyteir Therapeutics, Inc. (CYT) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying CYT?
Before investing in Cyteir Therapeutics, Inc. (CYT), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on publicly available sources and may be subject to change.
- AI analysis is pending and may provide additional insights.